University of Texas MD Anderson Cancer Center Sets Partnership With Bellicum Pharmaceuticals
September 02, 2021
September 02, 2021
HOUSTON, Texas, Sept. 2 (TNSPar) -- The University of Texas's MD Anderson Cancer Center issued the following joint news release on Sept. 1, 2021:
The University of Texas MD Anderson Cancer Center and Bellicum Pharmaceuticals, Inc. today announced a global option and license agreement covering certain intellectual property and technology rights regarding Bellicum's CaspaCIDe(R) (inducible caspase-9, or iC9) safety switch and related technologies, and the use of rimiducid, a . . .
The University of Texas MD Anderson Cancer Center and Bellicum Pharmaceuticals, Inc. today announced a global option and license agreement covering certain intellectual property and technology rights regarding Bellicum's CaspaCIDe(R) (inducible caspase-9, or iC9) safety switch and related technologies, and the use of rimiducid, a . . .